Head and neck cancer trials in Taiwan
43 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Where
- Changhua, Kaohsiung City, Tainan, Taipei
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT04198766 - Phase 3Taking peopleJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Where
- Bei Qu, Changhua, Keelung, Taichung, Taipei
- Age
- 60 years and over
- People
- 500 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00 - Phase 1/2Taking peopleA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Where
- Changhua, Kaohsiung City, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 287 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Changhua, Kaohsiung City, Taichung, Tainan, Taipei
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - Phase 2/3Taking peopleFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Where
- Changhua, Kaohsiung City, Taichung, Taipei
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00 - Phase 2Taking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Taipei
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - Phase 2/3Taking peopleOrdastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- Where
- Changhua, Kaohsiung City, Taichung, Tainan, Taipei, Taipei City
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT06295731 - Phase 1/2Taking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Changhua, Taipei
- Age
- 18 years and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - No phaseTaking peopleEffectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer
- Where
- Kaohsiung City
- Age
- 18 years and over
- People
- 36
- Run by
- Kaohsiung Medical University Chung-Ho Memorial Hospital
See details and how to joinNCT07306546 - Phase 2Taking peopleA Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Where
- Taichung, Taipei
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- AbbVie
See details and how to joinNCT07744126 · EU 2025-524179-22-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Taichung, Tainan, Taipei
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - No phaseTaking peopleLong-term Neurovascular Complications After Radiation Therapy in Head and Neck Cancer
- Where
- Taipei
- Age
- 20 years to 100 years
- People
- 800
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06111430 - Phase 1/2Taking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Kaohsiung City, New Taipei City, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Kaohsiung City, Taichung, Taipei, Taoyuan City
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1Taking peopleA Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Where
- Kaohsiung City
- Age
- 18 years and over
- People
- 110 worldwide
- Run by
- EpiBiologics
See details and how to joinNCT07462377 - Phase 3Taking peopleA Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Where
- Kaohsiung City, Taichung, Tainan, Taipei
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Changhua, Kaohsiung City, Taichung, Taipei, Taoyuan
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - No phaseTaking peopleCan Exercise Ameliorate Immunosenescence and Thereby Reduce Relapse in Head and Neck Cancer Patients
- Where
- New Taipei City
- Age
- 20 years to 80 years
- People
- 290
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06851988 - No phaseTaking peopleSkeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients
- Where
- New Taipei City
- Age
- 20 years to 80 years
- People
- 280
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06666881 - Phase 2Taking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Kaohsiung City, Taichung, Taipei
- Age
- 18 years to 64 years
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - Phase 2Taking peopleBoron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers
- Where
- Chiayi City, Taichung, Taipei
- Age
- 18 years to 80 years
- People
- 24
- Run by
- China Medical University Hospital
See details and how to joinNCT06952868 - No phaseTaking peopleFoot Reflexology and Ta-VNS for Symptom Management in Head and Neck Cancer During CCRT
- Where
- Hualien City
- Age
- 30 years to 75 years
- People
- 180
- Run by
- Tzu Chi University
See details and how to joinNCT07711626 - No phaseTaking peopleEffects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment
- Where
- Hualien City
- Age
- 30 years to 85 years
- People
- 102
- Run by
- Buddhist Tzu Chi General Hospital
See details and how to joinNCT07689019 - Phase 1Taking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Kaohsiung City, Taipei
- Age
- 18 years and over
- People
- 1,006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00